Development status: Approved, off-patent

Combination therapy

Mechanism of Action/Target pathogen: Binds irreversibly to beta-lactamases, mainly class A enzymes. No intrinsic antibacterial activity

Additional information: Semisynthetic, derived from sulbactam. Only available as a combination product, multiple fixed combinations, parenteral application